Targets › ROR1
4 programs from 4 companies in 11 trials: 5 Phase 2, 5 Phase 1, 1 Phase 3; Oncology; next expected readout Sep 2027.
Has very low kinase activity in vitro and is unlikely to function as a tyrosine kinase in vivo. Receptor for ligand WNT5A which activates downstream NFkB signaling pathway and may result in the inhibition of WNT3A-mediated signaling. (UniProt, Q01973)
Open in Phaseline: the race on ROR1, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Merck & Co. (MSD) | Cirmtuzumab (MK-2140) Inactive tyrosine-protein kinase transmembrane receptor ROR1 inhibitor | ROR1 | Phase 3 | Diffuse Large B-Cell Lymphoma; DLBCL; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Large B-Cell, Diffuse (DLBCL) … | Sep 2027 |
| Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical | TQB2101 for Injection anti-ROR1 antibody-drug conjugate | ROR1 | Phase 1 | Advanced Hematologic Malignancies | Jun 2028 |
| Shanghai EpimAb Biotherapeutics | EMB-07 Bispecific antibody targeting CD3 and ROR1 | CD3, ROR1 | Phase 1 | Combination Therapy | Jun 2028 |
| NEOK Bio | NEOK001 B7-H3 and ROR1 targeting bispecific antibody-drug conjugate | B7H3, ROR1 | Phase 1 | Locally Advanced (Unresectable) or Metastatic Solid Tumors | Jan 2029 |
Chronic Lymphocytic Leukemia (2) Diffuse Large B-Cell Lymphoma (1) DLBCL (1) Lymphoma, Large B-Cell, Diffuse (1) Lymphoma, Large B-Cell, Diffuse (DLBCL) (1) Urothelial Carcinoma (1) B-cell Acute Lymphoblastic Leukemia (1) Locally Advanced (Unresectable) or Metastatic Solid Tumors (1) Advanced Hematologic Malignancies (1) Combination Therapy (1)
mixed (2), small molecule (2)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.